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ABSTRACT
Understanding cancer stem cell (CSC) maintenance pathways is critical for the 
development of CSC-targeting therapy. Here, we investigated the functional role of the 
cyclin D1-dependent activation of Smad2/3 and Smad4 in hepatocellular carcinoma 
(HCC) CSCs and in HCC primary tumors. Cyclin D1 sphere-derived xenograft tumor models 
were employed to evaluate the therapeutic effects of a Smad inhibitor in combination 
with chemotherapy. Cyclin D1 overexpression confers stemness properties by enhancing 
single sphere formation, enhancing the CD90+ and EpCAM+ population, increasing 
stemness gene expression, and increasing chemoresistance. Cyclin D1 interacts with 
and activates Smad2/3 and Smad4 to result in cyclin D1-Smad2/3-Smad4 signaling-
regulated liver CSC self-renewal. The cyclin D1-dependent activation of Smad2/3 and 
Smad4 is also found in HCC patients and predicts disease progression. A Smad inhibitor 
impaired cyclin D1-Smad-mediated self-renewal, resulting in the chemosensitization. 
Thus, pretreatment with a Smad inhibitor followed by chemotherapy not only successfully 
suppressed tumor growth but also eliminated 57% of the tumors in a cyclin D1 sphere-
derived xenograft model. Together, The cyclin D1-mediated activation of Smad2/3 and 
Smad4 is an important regulatory mechanism in liver CSC self-renewal and stemness. 
Accordingly, a Smad inhibitor induced CSC differentiation and consequently significant 
chemosensitization, which could be an effective strategy to target CSCs.
INTRODUCTION
Cancer stem cells (CSCs) represent a distinct 
population that can be isolated from tumor tissues and 
exhibit long-term clonal repopulation and self-renewal 
capacity [1, 2]. Cancer cells are equipped with apoptotic 
block, high drug transporter expression, efficient DNA 
repair and quiescence, which are the mechanisms of therapy 
resistance. Interestingly, these mechanisms are also active 
in CSCs [3, 4]. Despite these known mechanisms, the 
stemness properties of a cancer cell are the core contributors 
to clinical therapy failure and recurrence. Thus, the 
therapeutic targeting stem cell maintenance pathways may 
be an effective means to eliminate CSCs [1], though only if 
the mechanisms of controlling self-renewal are differentially 
active in malignant versus normal stem cells [2]. An 
advanced study has demonstrated that the use of a stemness 
inhibitor (small molecule) effectively blocked relapse and 
metastasis in xenografted human cancers [5]. Alternatively, 
inducing CSC differentiation may be a promising treatment 
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direction. BMP (member of TGF-β family) induces glial 
differentiation in glioblastomas and consequently attenuates 
tumor growth [2]. Using all-trans retinoic acid (ATRA) to 
treat BCR–ABL-expressing chronic myeloid leukemia cells 
induced differentiation to prevent the acquisition of tyrosine 
kinase inhibitor (TKI) resistance [6]. Thus, targeting cancer 
stemness and inducing differentiation are novel strategies 
for cancer therapy.
Cyclin D1 binds and activates CDK4/CDK6 and 
phosphorylates retinoblastoma protein (Rb) to promote 
the activation of E2F-responsive genes, which facilitate 
the transition of cells from the G1 to the S phase of the 
cell cycle and initiate DNA synthesis. Thus, the primary 
biological function of cyclin D1 is the promotion of cellular 
proliferation [7, 8]. Cyclin D1 is also a well-established 
human oncogene and is important for the development and 
progression of several cancers [7]. However, this relationship 
is less apparent in human hepatocellular carcinoma (HCC), 
for which only CCND1 870G>A polymorphism has been 
suggested as a risk factor of HCC [9].
Recently, studies have demonstrated the roles of 
cyclin D1 in stem cell regulation. Specifically, cyclin 
D1 promotes somatic reprogramming efficiency by 
enhancing the S phase and cellular proliferation [10, 11], 
although cyclin D1 does not play a role in promoting 
induced pluripotent stem cells (iPSCs) maturation 
towards a complete reprogramming [12]. Constitutive 
overexspression of cyclin D1 prevents early G1 phase 
of human embryonic stem cells (hESCs) to initiate 
differentiation, whereas it induces late G1 phase hESC 
differentiation by suppressing Smad2/3 transcription and 
localization [13, 14]. In addition to the correlation between 
cyclin D1 and Smad2/3 for cell fate coordination via G1 
compartmentalization, Smad2/3 is also a key effector in 
Nodal/Activin signaling, which is an essential pathway for 
the pluripotency of hESCs [15, 16].
Cyclin D1 is deregulated in many types of cancers, 
but the functional role of cyclin D1 and its association 
with TGF-β/Smad signaling in CSC regulation is yet to be 
defined. In the present study, we demonstrated that cyclin 
D1-Smad2/3-Smad4 is an important signaling pathway in 
liver CSC self-renewal. We further evaluated the efficacy 
of a Smad inhibitor to induce CSC differentiation and 
chemosensitization to ultimately suppress cyclin D1-
expressing sphere-derived xenograft tumors.
RESULTS
Cyclin D1 promotes liver CSC spherical cell 
proliferation and chemoresistance
To examine whether cyclin D1 regulates liver CSC 
proliferation, HCC 97H cells (a HCC tumor-derived 
primary cell line) and Huh7 cells (Supplementary Figure 
1A, 1B) were transfected with lentiviral-cyclin D1 vector. A 
cancer anchorage-independent spherical colony assay was 
performed for all experiments because CSCs can be enriched 
in spherical cells [17]. Cyclin D1 overexpression resulted in 
increased overall anchorage-independent spherical colony 
(spheres) formation in two lines of HCC cells (Figure 1A, left 
panel). The capacity of secondary and third sphere formation 
from dissected single spherical cells was significantly higher 
in cyclin D1-expressing than in vector-expressing cells 
(Figure 1A, right panel), where single sphere formation 
reflects more self-renewal ability. For the same and longer 
culturing periods, cyclin D1-expressing spheres maintained 
a spherical morphology, whereas vector-expressing spheres 
differentiated (Figure 1B). In addition to promoting self-
renewal, cyclin D1 expression promoted spherical cell 
proliferation, as evidenced by an increased number of cells 
in the S phase (Supplementary Figure 1C) and increased cell 
mobility (according to a Transwell assay) (Supplementary 
Figure 1D, 1E). These phenomenon could be explained by 
cyclin D1-mediated increased expression of transcription 
factor E2F1 (Figure 1C), as cyclin D1-CDK4 complex 
activates Rb and E2F1 to promote cell cycle progression and 
cellular proliferation [7].
Cyclin D1 expression conferred liver cancer cells 
with more CSC- and SC-like features, such as increased 
CD90+ and EpCAM+ liver CSC populations [18] in 
spherical cancer cells (Figure 1D), as well as in attached 
cancer cells (Supplementary Figure 1F), and enhanced 
mRNA levels of the pluripotency-associated genes 
NANOG, OCT4, SOX2, NODAL and ACTIVIN (Figure 
1E, Supplementary Figure 1G). Glycolysis is a metabolic 
requirement for stem cells [19]. Cyclin D1 also enhanced 
the expression of glycolytic genes (Figure 1F). More 
importantly, cyclin D1-expressing spheres were highly 
resistant to conventional chemotherapeutic drugs (Figure 
1G). Taken together, these data show that cyclin D1 
expression increased the CSC population and promoted 
the self-renewal capacity of CSC, which consequently led 
to chemotherapy resistance.
Cyclin D1 regulates the activity of Smad2/3 and 
Smad4
Activin/Nodel signaling is essential for the self-
renewal of hESCs, and Smad2/3 is a main effector of this 
pathway [15, 16]. The levels of cyclin D proteins have 
been shown to modulate Smad2/3 activity although it 
is restricting to the G1 phase of the cell cycle in hESCs 
[13, 14]. We hypothesize that the regulation of cyclin 
D1 on Smads might not be limited in G1 phase, we next 
determined whether and how cyclin D1 regulates Smad2/3 
and Smad4 in HCC CSCs. In cyclin D1-overexpressing 
spherical cancer cells, Smad2/3 phosphorylation and the 
total level of Smad4 were enhanced, as shown by Western 
blots and flow cytometry (Figure 2A, 2B). Importantly, a 
co-IP analysis revealed the interaction of cyclin D1 with 
both Smad4 and Smad2/3, and cyclin D1 precipitated more 
Smad4 and Smad2/3 proteins in cyclin D1-overexpressing 
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cells than in controls (Figure 2C). These results suggest 
that (a) cyclin D1 indeed interacted with Smad2/3 and 
Smad4 in vitro; (b) cyclin D1 expression enhanced 
Smad2/3 phosphorylation and Smad4 expression in 
liver cancer cells; (c) cyclin D1 may mediate liver CSC 
features via TGF-β/Smad signaling, a critical pathway for 
self-renewal. Moreover, cyclin D1 overexpression also 
led to an increased phosphorylation of Akt but not Erk1/2 
(Supplementary Figure 2A, 2B).
Association between cyclin D1 and Smad2/3 and 
Smad4 in HCC patients
We next assessed the interaction of cyclin D1 and 
Smad in HCC primary tumors. To this end, we measured 
the protein levels of cyclin D1, phospho-Smad2/3, and 
Smad4 in 40 of HCC tumor tissues. Many HCC patients 
expressed high levels of the three tested proteins; 
specifically, high cyclin D1 was related to high pSmad2/3 
Figure 1: Cyclin D1 expression confers liver cancer cells with CSC and SC features. (A) Overall sphere formation (left 
panel) and secondary and third sphere formation from dissected single spherical cells (right panel) in vector- or cyclin D1-expressing Huh7 
and 97H cells. (B) Phase contrast image of vector- (upper panel) and cyclin D1-expressing (lower panel) liver cancer spherical colonies. 
(C) mRNA levels of E2F1 in vector and cyclin D1-expressing spheres. qRT-PCR data are represented as the mean ± SD, n = 2. (D) Flow 
cytometry analysis of the CD90+ and EpCAM+ population in vector- or cyclin D1-expressing spherical cells shown by both dot blot and 
histogram. (E) mRNA levels of the stemness genes NANOG, OCT4, SOX2, NODAL, and ACTIVIN. qRT-PCR data are represented as 
the mean ± SD, n = 3 (from different spheres); each experiment was conducted in duplicate. The vector- and cyclin D1-expressing spheres 
were statistically compared with a paired Student’s t test (*, p < 0.05; **, p < 0.01; ***, p < 0.001). (F) qRT-PCR of glycolytic genes, 
GLUT1, PFK1, HK2, and LDHA. (G) Sphere formation capability of vector- or cyclin D1-expressing spheres after cisplatin (0.5-0.8 μg) 
and doxorubicin (0.1-0.2 μg) treatments.
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expression (Figure 2D, asterisk on the top), high cyclin D1 
was related to high Smad4 expression (Figure 2D, asterisk 
at the bottom), and high cyclin D1 expression was related 
to both high pSmad2/3 and Smad4 expression (Figure 
2D, patients 1669T, 1834T, 2364T, 1454T, 1502T, 1524T, 
and 1574T). Protein levels of cyclin D1, pSmad2/3, and 
Smad4 of normal liver tissues were also presented (Figure 
2D). Based on a linear regression analysis, 52.5% of 
HCC patients displayed significant cyclin D1-dependent 
pSmad2/3 expression (Figure 2E, Supplementary Figure 
2C), and 55% of patients exhibited cyclin D1-dependent 
Smad4 expression (Figure 2F, Supplementary Figure 
2D). Clinically, high cyclin D1 levels were significantly 
associated with late-stage HCC, tumor venous infiltration, 
and ≥ 2 tumor nodules (Table 1). More importantly, 
overall survival was significantly reduced in patients 
expressing high levels of cyclin D1, pSmad2/3, and 
Smad4 (Figure 2G, p = 0.025). Thus, cyclin D1 physically 
and functionally interacts with pSmad2/3 and Smad4 in 
both HCC cells and HCC primary tumor tissues, which 
further implicates in the pathogenesis of the disease, such 
as a poor prognosis for HCC patients.
Figure 2: Cyclin D1-dependent activation of Smad2/3 and Smad4. (A) Western blot analysis of cyclin D1, phospho-
Smad2/3, Smad2/3, Smad4 in cyclin D1 spheres compared with vector spheres. (B) Flow cytometry analysis in dot blot and histogram 
to quantitate pSmad2/3 expression in vector- or cyclin D1-expressing spheres. (C) Vector- or cyclin D1-expressing sphere lysates were 
immunoprecipitated with cyclin D1 antibody; the bound proteins were analyzed using Smad2/3 or Smad4 antibody. (D) Representative 
western blots of cyclin D1, pSmad2/3, Smad4, and β-actin from 40 HCC primary tumor tissues and normal donor (ND) liver tissue. 
Asterisks indicate an association between the expression pattern of cyclin D1 and pSmad2/3 (top) or Smad4 (Bottom). (E) Linear regression 
analysis of the cyclin D1-dependent expression of pSmad2/3 using quantitated levels of (D). (F) Linear regression analysis of the cyclin 
D1-dependent expression of Smad4 in HCC patients. (G) Kaplan-Meier analysis of the overall survival of HCC patients comparing high 
and low cyclin D1, pSmad2/3, and Smad4 expression.
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Smad4 and Smad2/3 confer liver CSC self-
renewal capacity
TGF-β/Smad signaling exerts multiple effects on 
normal stem cell biology [15], whereas the knowledge 
of its role in CSCs is limited. Based on the cyclin D1-
mediated activation of pSmad2/3 and Smad4 expression 
(Figure 2), we next assessed whether it is activated 
Smad2/3 and Smad4 driving the self-renewal of CSC. 
The overexpression of Smad2 and Smad4 significantly 
increased the numbers of spherical colonies derived from 
monolayer cells (Figure 3A). The formed spheres were 
further dissected into single cells, and 68% of single 
Smad2-expressing cells grew spherical colonies, whereas 
53.5% of vector-expressing single cells were unable to 
grow spheres (Figure 3B). In the same culturing period, 
96% of Smad4-expressing spherical cells maintained 
non-differentiated states, whereas 75% of control spheres 
differentiated (Figure 3C, 3D). The activation of Smad2/3 
and Smad4 are the intracellular effectors of Nordal/
Activin signaling, which regulates the self-renewal of stem 
cells [15, 16, 20]. To assess the effect of Smad expression 
on stemness features, we measured the gene expression 
of NANOG, OCT4, and SOX2, which were significantly 
increased (Figure 3E). Moreover, the liver CSC CD90+ 
population was also larger (Figure 3F). The results 
suggest that Smad2/3 and Smad4 control cancer spherical 
cell self-renewal by promoting CSC sphere proliferation 
and preventing CSC sphere differentiation. Because 
TGF-β signaling is known to trigger the expression of 
epithelial-mesenchymal transition (EMT)-promoting 
factors [21], we also assessed the expression of epithelial 
and mesenchymal markers. Accordingly, we discovered 
that the overexpression of Smad2 and Smad4 promoted 
EMT gene expression. Specifically, the epithelial markers 
E-CADHERIN (CDH1) and CK19 (Figure 3G, left panel) 
were down-regulated, and the mesenchymal markers 
SNAIL1, SNAIL2, and N-CADHERIN (CDH2) were 
up-regulated (Figure 3G, right panel). In addition, the 
expression of the chemo-resistant gene ABCB1, but not 
that of ABCG2, was enhanced in Smad-expressing cells 
(Figure 3G, right panel). Thus, via activating Smad2/3 
and Samd4, cyclin D1 regulates the self-renewal ability 
of liver CSCs by enhancing stemness gene expression, 
growing the CSC population, and promoting EMT.
Targeting Smad impairs liver CSC self-renewal
Given the strong association between cyclin D1 
and Smad in controlling liver CSC proliferation, we next 
applied SB431542 (SB), an inhibitor of activin receptor-
like kinase (ALK) receptors, to suppress Smad activation 
and consequently, CSC self-renewal. The addition of 
SB431542 to cyclin D1-expressing spheres reduced 
the populations of CD90+, EpCAM+, and CD133+ 
cells, which are three liver CSC markers (Figure 4A) 
(Supplementary Figure 3A); similarly, stemness gene 
(NANOG, OCT4, and SOX2) expression was also reduced 
(Figure 4B). Interestingly, Smad inhibitor treatment 
reversed EMT by increasing E-CADHERIN and CK19 
gene expression (Figure 4C), decreasing SNAIL1/2 
and N-CADHERIN gene expression (Figure 4D), and 
functionally reducing cellular mobility (Supplementary 
Figure 3B, 3C). In addition to promoting cancer 
metastasis, the induction of EMT has been associated with 
the acquisition of molecular and functional traits of CSCs 
[21, 22], such as enriched cancer spherical cells and CSC 
markers; therefore, EMT reversal at the gene expression 
level might additionally inhibit CSC proliferation. 
Furthermore, a high rate of glycolysis is a metabolic 
signature of CSCs (Warburg effect version 2.0) [23] 
that is responsible for maintaining the undifferentiated 
state of these cells [24]. TGF-β/Smad signaling has been 
known to cross-regulate the PI3K/Akt pathway, which 
increases glucose uptake and glycolysis [25]. Because 
cyclin D1 enhanced activation of Akt (Supplementary 
Figure 2A) and glycolytic gene expression (Figure 1E), 
we examined the effect of SB431542 on glycolysis. In 
cyclin D1-expressing spheres, this agent significantly 
inhibited glycolytic gene expression (Supplementary 
Table 1: Correlation between clinicopathological parameters and cyclin D1
Parameters Category Cases
(n=40)
Cyclin D1 level 
(median)
P
Tumor UICC7 stage I-II 30 12.2 0.004
III-V 10 23
Tumor size ≤ 20 mm 14 27.5 0.12
> 20 mm 13 25.3
Tumor nodules (no.) 1 nodeul 24 12 0.002
≥ 2 nodeuls 16 32.5
Venous infiltration absent 22 11.8 0.04
present 18 26
Oncotarget38816www.impactjournals.com/oncotarget
Figure 3D) and moderately reduced the glycolytic rate, 
as measured by lactate production (Supplementary Figure 
3E). These results all indicate that SB431542 reduced the 
stemness of cyclin D1-expressing spheres. Consequently, 
the application of Smad inhibitor significantly but 
moderately reduced overall CSC sphere formation in vitro 
(Figure 4E). The inhibition was specifically effective in 
cyclin D1-expressing spheres but not in parental spheres 
(Supplemenatry Figure 3F). In addition, Mek-Erk inhibitor 
(U0126) did not inhibit cyclin D1-expressing spheres 
(Supplementary Figure 3G). These data not only further 
prove the cyclin D1-mediated activation of Smad2/3 but 
also demonstrate that cyclin D1-Smad is a functional 
pathway that regulates liver CSC self-renewal.
Figure 3: Smad4 and Smad2 expression promotes self-renewal and EMT. (A) Sphere formation capacity of 97H cells that had 
been transfected with empty vector and vector encoding Smad4 or Smad2. (B) Spheres from (A) were dissected for single sphere formation, 
and the percentages of cells that formed spheres and those that did not were statistically compared. (C) Percentages of differentiated versus 
non-differentiated spheres in vector- or Smad4-expressing HCC cells. (D) Phase contrast images of differentiated and non-differentiated 
sphere colonies. (E) mRNA levels of NANGO, OCT4, and SOX2 in vector- versus Smad4-expressing spheres. (F) Flow cytometry 
histogram of CD90+ populations in vector-, Smad2-, or Smad4-expressing spheres. (G) mRNA levels of the EMT genes CDH1 and CK19 
(left panel); SNAIL1, SNAIL2, and CDH2, and the multidrug resistance gene ABCB1 (right panel) in vector- versus Smad2-expressing 
and Smad4-expressing spheres.
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Figure 4: Effects of Smad inhibitor on liver CSCs. (A) Flow cytometry analysis of the CD90+, EpCAM+, and CD133+ 
population in cyclin D1-expressing spheres after treatment with the Smad inhibitor SB431542. (B) NANOG, OCT4, and SOX2 expression 
in cyclin D1-expressing spheres treated with SB431542 versus DMSO. (C) Expression of the epithelial genes CDH1 and CK19 and 
(D) the mesenchymal genes SNAIL1, SNAIL2, CDH2 and ABCB1 after SB431542 treatment. (E) Relative sphere viability of cyclin D1-
expressing spheres treated with various doses of SB431542 (10, 30, or 40 μM) versus DMSO. (F) Percentage of differentiated spherical 
colonies after SB431542 (20-30 μM) treatment. (G) Phase contrast image of spherical colonies treated with SB431542 versus untreated 
control. (H) Sphere viability of cyclin D1-97H spherical cells treated with cisplatin alone, SB431542 in combination with cisplatin (SB 
+cis), or SB431542 pre-treatment followed by cisplatin (SB >cis). SB431542 all in low dose (10 μM). (I) Same assay as described in (H) 
in cyclin D1-Huh7 spherical cells.
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Smad inhibitor induces CSC differentiation and 
chemosensitization
The observed cyclin D1-Smad-mediated CSC self-
renewal provides the logical basis for targeting Smad 
to inhibit CSC proliferation. However, Smad inhibitor 
treatment only moderately suppressed the growth of 
cyclin D1-expressing spheres, and more than 40-60% of 
cells survived in response to the highest dose of SB431542 
(Figure 4E). Furthermore, more than 80% of survived 
spheres were differentiated cells in response to a low dose 
of SB431542 (Figure 4F, 4G). Importantly, these surviving 
spheres lost their stemness characteristics (Figure 4A-4D, 
Supplementary Figure 3D). Thus, Smad inhibition drives 
cyclin D1-expressing CSCs into a more differentiated 
state, letting an expectation that these cells may become 
sensitization to chemotherapy. To determine whether the 
addition of Smad inhibitor can chemosensitize highly 
resistant cyclin D1-expressing spheres (Figure 1F), we 
first simultaneously applied SB431542 (SB) and cisplatin 
(cis) (SB +cis). The addition of low-dose SB431542 (10 
μM) and cisplatin resulted in a survival rate of over 50%-
70% in 97H-cyclin D1 spheres (Figure 4H) and Huh7-
cyclin D1 spheres (Figure 4I). We then pre-treated cells 
with a low dose of SB431542 (10 μM) to induce the 
differentiation of cyclin D1-expressing spheres, which 
was followed by chemotherapeutic drug treatment (SB 
>cis). This strategy significantly sensitized cells to three 
therapy drugs cisplatin, oxaliplatin (oxa), and doxorubicin 
(dox) in both 97H- and Huh7-cyclin D1 spheres (Figure 
4H, 4I), and the lowest survival rate was less than 20% 
in 97H-spheres (Figure 4H). When spheres were cultured 
for longer periods before the addition of SB431542 and 
subsequent addition of therapy drugs, Smad inhibitor 
continued to effectively induce chemosensitization 
(Supplementary Figure 3H). In highly resistant spherical 
cancer cells, which results from enhanced self-renewal via 
cyclin D1 and cyclin D1-dependent activation of Smad2/3 
and Smad4 (Figures 1–3), inducing differentiation with 
Smad inhibitor is a critical tactic for turning resistant CSCs 
into therapy-sensitive cells. Thus, impaired self-renewal 
and the induction of differentiation are the molecular basis 
by which combination therapy eliminates CSCs.
Differentiation and chemosensitization 
suppresses cyclin D1-expressing xenograft tumor
A cyclin D1 sphere-derived xenograft tumor 
model was used to evaluate whether the induction of 
differentiation may serve as a strategy to target CSCs in 
vivo. Specifically, we compared the effects of therapy in 
different experimental setups (Figure 5A). When treating 
with Smad inhibitor alone, only a high dose of SB431542 
(40 μg/kg/week) inhibited tumor growth (Figure 5B). 
Interestingly, administering a low dose of SB431542 
and cisplatin simultaneously (SB +cis) did not suppress 
tumor growth (Supplementary Figure 4A, 4B), and this 
finding is similar to the results obtained in vitro (Figure 
4H, 4I). Thus, even combination therapy has little impact 
when tumor cells are primarily in the CSC state. However, 
first injecting the same dose of SB431542 and then 
subsequently administering cisplatin (SB >cis) rendered 
the combination therapy effective. Moreover, we observed 
tumor growth kinetics based on the bioluminescence 
signals of xenograft tumors, which remained low in the 
SB >cis group, whereas the bioluminescence signals 
continued to increase in the cisplatin group (Figure 
5C, 5D). The tumor volume at the endpoint was also 
significantly decreased (Figure 5E, 5F). Importantly, we 
observed a 57% elimination of tumor mass (based on a 
total of 14 subcutaneous cell injections) in response to 
Smad inhibitor pre-treatment followed by chemotherapy. 
The tumor incidence in the SB >cis treatment group was 
43%, whereas it was 100% in all other control groups 
(vehicle, Smad inhibitor alone, cisplatin alone, or SB 
+cis) (Figure 5G). We hypothesized that Smad inhibitor 
impaired CSC stemness and induced CSC differentiation 
to render combination therapy effective. Therefore, we 
assessed the CSC population and self-renewal ability 
of xenograft tumor tissue at the endpoint. Compared 
with control-treated tumor, SB >cis treatment decreased 
the CSC CD90+ population by 11-fold. In contrast, cis 
treatment alone resulted in only a 1.6-fold decrease in the 
CD90+ population (Figure 5H, Supplementary Figure 4C). 
In addition, overall (Supplementary Figure 4D) and single 
(Figure 5I) sphere formation was significantly reduced in 
the SB >cis group, indicating reduced stemness features in 
this tumor tissue. These results demonstrate that standard 
chemotherapy is not effective for spherical cancer cell-
derived tumors, for which decreasing stemness by 
inducing differentiation via a SB >cis treatment regimen 
is the key to chemosensitization.
In vitro Smad inhibition in CSC reduces in vivo 
tumorigenecity
For the subsequent investigation, we assessed 
the in vivo tumorigenicity of cells pretreated with 
Smad inhibitor. Cyclin D1-expressing spheres were 
exposed to DMSO or SB431542 in vitro. All surviving 
cells were subjected to single cell sphere formation or 
subcutaneously injected into immunodeficient mice for 
xenograft tumor formation (Figure 6A). No further in vitro 
and in vivo treatment was administered. The single cell 
sphere formation rate was 66% in the DMSO-pre-treated 
group versus 33% in the SB431542-pre-treated group 
(Figure 6B). Xenograft tumorigenicity was determined at 
5 weeks. In vitro Smad inhibitor pre-treatment partially 
eradicated tumorigenicity in vivo by reducing the tumor 
incidence, which was 100% in the DMSO group and 
64% in the SB431542 group (Figure 6C); Smad inhibitor 
pre-treatment also significantly reduced tumor volume 
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Figure 5: In vivo effects of Smad inhibitor-mediated chemosensitization. (A) Schematic experimental setup for the treatment 
of a cyclin D1 sphere-derived xenograft tumor model. (B) Tumor volume 4 weeks after treatment with different doses of SB431542 
alone. (C) Tumor growth kinetics based on the luciferin bioluminescence signal in cisplatin versus pre-SB431542 followed by cisplatin 
treatment. Data are the means ± SD; n = 8 (injection). (D) Representative tumor images based on the luciferin bioluminescence of (C). 
(E) Statistical comparison of the tumor volume at the endpoint (6 weeks). (F) Representative tumor mass (C) at the endpoint. Scale 
bar = 1 cm. (G) Summary of tumor incidence (%) of respective treatment groups: vehicle, cisplatin alone, SB431542 alone, SB431542 + 
cisplatin simultaneously (SB +cis), or SB431542 pretreatment followed by cisplatin (SB >cis). (H) The xenograft tumor tissue was digested 
at the endpoint to detect the CD90+ population. The percentage of the CD90+ population of the control was defined as 1 for the fold-change 
of treatment groups. The fold decrease in the CD90+ population in the cis or SB >cis group was calculated as the inverse of the fold change. 
(I) The xenograft tumor tissue was digested and cultured for a few days, followed by single sphere formation. The single sphere formation 
capacity in the control was defined as 1, the fold decrease in the cis or SB >cis group was calculated as the inverse of the fold change.
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(Figure 6D, 6E). Thus, Smad inhibitors can drive cyclin 
D1-Smad-mediated CSC into a more differentiated state 
that is sensitive to chemotherapy at the cellular level and 
minimizes tumorigenicity at the in vivo xenograft tumor 
level (Figures 4H, 4I, 5C–5G, 6C–6E).
DISCUSSION
Cyclin D1, in combination with a great number of 
oncogenes, CDK inhibitors, oncogenic growth factors, 
and transcription factors, transforms normal cells into a 
carcinogenic lineage [26, 27]. New functions of cyclin 
D1 have been identified, including the enhancement 
of cellular migration and invasion, angiogenesis, DNA 
damage repair, and the induction of chromosomal 
instability [28], which has expanded the known roles 
of cyclin D1 in cancers. In this study, we demonstrated 
the biological function of cyclin D1 in liver cancer 
spherogenesis, which consists of enhancing liver CSC 
population and the expression of stemness transcription 
factors, which increases chemotherapy resistance. Thus, 
in addition to transformation and carcinogenesis, we 
demonstrate a new role for cyclin D1 in controlling liver 
CSC self-renewal and proliferation. Cyclin D1-mediated 
Figure 6: Decreased in vivo tumorigenecity of pretreated cells. (A) Schematic experimental setup. Cyclin D1-spheres were 
pretreated with SB431542 (20 μM for two times) or DMSO, followed by single sphere formation and in vivo tumorigenicity assays, without 
further treatment. (B) Statistical comparison of single cells that formed spheres and those that did not. (C) Xenograft tumor incidence (%) 
at 5 weeks for the injection of pretreated cells (n = 14). (D) Statistical comparison of tumor volume at the endpoint. (E) Representative 
tumor size based on bioluminescence imaging (upper panel) and tumor mass (lower panel) at the endpoint. Scale bar = 1 cm. (F) Schematic 
summary of Cyclin D1-Smad2/3-Smad4 axis and therapeutic potential of Smad inhibitor.
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increases in stemness-CSC properties may contribute to 
therapy failure and cancer recurrence.
TGF-β/Smad signaling is an important effector of 
a variety of signaling pathways that regulate the self-
renewal of normal and cancer stem cells. Cyclin D1 acts 
as an essential regulator of early cell fate decision during 
the G1 phase of hESCs by controlling the transcriptional 
activity of Smad2/3 [13, 14]. Here, we demonstrated that 
cyclin D1 interacts with and activates Smad2/3 and Smad4 
to regulate liver CSC self-renewal. Moreover, this study 
is the first to demonstrate cyclin D1-dependent pSmad2/3 
and Smad4 expression in clinical HCC primary tumors, 
in which the association implicated a poor prognosis. 
Therefore, by maintaining stemness and the proliferation 
of CSCs in HCC tumors, cyclin D1-Smads signaling may 
be a critical contributor to clinical cancer poor prognosis 
and conventional treatment failure. Moreover, activated 
Smad2/3 and Smad4 are functional effectors of several 
signaling pathways that regulate pluripotency [15, 16, 
20]. Similarly, we found that the expression of Smad2/3 
and Smad4 directly promotes liver cancer spherogenesis 
and consequently confers these cells with high stemness 
and CSC properties. In addition, Smad2/3 and Smad4 
expression promoted the EMT phenotype, which further 
aided the acquisition of self-renewal traits. Thus, liver 
cancer cells appear to hijack Smad2/3 and Smad4 for 
CSCs, and this process is closely associated with oncogene 
cyclin D1 regulation (Figure 6F).
The CSC population has a capacity for long-term 
repopulation and is highly resistance to chemotherapy or 
even targeted therapy, which results in therapy failure or 
cancer recurrence after regression. Therapy approaches 
that target CSCs have centered on the following: (1) 
eliminating specific marker-bearing CSCs, (2) treatment 
with drugs or small molecule that target cancer stemness, 
such as upstream transcriptional factors or signaling 
pathways, and (3) the induction of CSC differentiation 
to attenuate tumor growth [1, 2, 5]. Cyclin D1-dependent 
activation of Smad2/3 and Smad4 provides the possibility 
of utilizing Smad inhibitors for targeting CSCs. Indeed, 
the application of SB431542 reduced cyclin D1-
expressing liver CSC spherogenesis and sphere-derived 
tumor growth, although the inhibition efficacy was limited 
with no xenograft tumor could be eradicated. However, 
treatment with a Smad inhibitor significantly impaired 
the stemness of CSCs, suggesting that the surviving 
CSCs were differentiated. Based on this hypothesis, the 
therapy regimen was adjusted by an initial treatment with 
Smad inhibitor (low dose), followed by conventional 
chemotherapy. This adjusted treatment resulted in 
significant chemosensitization. This unique combination 
therapy regimen not only inhibited tumor growth but it also 
more effectively eradiated 57% of xenograft tumors. Thus, 
CSC differentiation may be a critical step in overcoming 
resistance and ensuring the effectiveness of conventional 
therapy (Figure 6F). Moreover, the ineffectiveness of the 
simultaneous administration of low dose Smad inhibitor 
and cisplatin in both CSC spherogenesis and xenograft 
models may be associated with the drug administration 
process, which may not result in CSC differentiation.
In conclusion, this study identified cyclin D1 and 
cyclin D1-depemdent activation of Smad2/3 and Smad4 
regulatory mechamins in HCC spherical cells, which 
functions in acquisition the CSC characteristics including 
the self-renewal, CSC markers and stemness gene 
expression, and chemoresistance. Cyclin D1-dependent 
activation of Smad2/3 and Smad4 is also reflected in HCC 
patients with poor prognosis. Targeting Smad followed by 
conventional therapy induces CSC differentiation resulting 
in significant chemosensitization in cyclin D1-spheres and 
cyclin D1-sphere-derived xenograft tumor, highlighting 
the usage of small molecule (Smad inhibitor) to induce 
CSC differentiation and chemosensitization could be an 
effective strategy for targeting CSCs.
MATERIALS AND METHODS
Cell culture and CSC sphere assay
The HCC lines MHCC97H (97H) and Huh7 
were cultured in DMEM supplemented with 10% FBS 
(Life Technologies) at 37°C and 5% CO2. 97H cells 
were isolated from a male metastatic HCC patient [29] 
and transfected with luciferase. Liver cancer spheres 
were generated in DMEM:F12 (Life Technologies) 
supplemented with 2% B-27 (Life Technologies), EGF, 
bFGF (PeproTech), 100 IU/ml penicillin, and 100 μg/
ml streptomycin on low attachment or polyHEMA-
coated plates for 10-14 days. The resultant cell spheres 
were dissociated with TrypLE (Life Technologies) and 
serially diluted for single spherical cell formation. The 
second generation of single spherical cells was expanded 
for all further experiments. The number of cells in 
spherical colonies larger than 50-100 μm was counted. 
For the chemotherapy drug or inhibitor treatment studies, 
doxorubicin in 0.2-0.8 μg (Main Luck Pharmaceuticals), 
cisplatin in 0.25-0.8 μg (Mayne Pharma), oxaliplatin in 1-2 
μg (Jiang su heng rui medicine co.), and TGF-β inhibitor 
SB431542 in 10-40 μM (Merck) were administered 2-3 
times. Cell mobility was detected by a transwell migration 
assay as described previously [30].
Vectors and transfection
The human cyclin D1 gene was amplified by PCR 
and cloned into the pWPI-lentiviral vector (Addgene). 
The lentiviral particles were produced in 293T cells using 
ViraPower Lentiviral Packaging Mix (Life Technologies) 
and concentrated by ultracentrifugation (20,000 g). 97H 
and Huh7 cells were infected with 1 ml of cyclin D1 
lentivirus for 24-48 h and then cultured in normal medium. 
The transfection efficiency was determined based on the 
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GFP-positive populations in both monolayer and spherical 
cells (Supplementary Figure 1A, 1B). The vectors encoding 
human Smad2 (pCMV5 Smad2-HA) and Smad4 (pcDNA 
Flag-Smad4M) were purchased from Addgene. 97H cells 
were transfected with Smad2 and Smad4 plasmids using 
Lipofectamine 2000 (Life Technologies) and then subjected 
to selection with 200 μg of G418 for 4 weeks.
Western blot and co-immunopricipitation (co-IP)
PVDF membranes containing electrophoretically 
separated proteins from human HCC tumor tissue and whole 
cell lysates from spherical cells were probed with antibodies 
against cyclin D1, phospho-Smad2/3, Smad2/3, Smad4 (Cell 
Signaling Technology), and β-actin (Sigma-Aldrich). The 
resultant immune complexes were visualized using enhanced 
chemiluminescence detection reagents (Bio-Rad). In vitro 
protein interaction was assessed based on co-IP using cyclin 
D1 and Smad4 or Smad2/3 antibodies. Briefly, 100-200 μg 
of total cell lysate was incubated with cyclin D1 antibody 
overnight, followed by incubation with a 50% protein G 
sepharose bead slurry (Amersham Biosciences) for 2 h. 
After 5 washes, the immune-complexes were analyzed by 
immunoblotting with anti-Smad4 or Smad2/3 antibodies.
qRT-PCR
Total RNA was extracted using an RNeasy kit 
(Qiagen), treated with DNase I, and then reverse-
transcribed with the Transcriptor First Strand cDNA 
Synthesis Kit (Roche). Quantitative PCR was performed 
using the Selected SYBR Green master mix (Life 
Technologies) on an ABI 7900HT Detection System. 
The PCR primers are listed in supporting information 
Supplementary Table 1. Gene expression was quantified 
based on the CT value and normalized to the levels of 18S.
Flow cytometry
To identify the liver CSC population, the cells were 
labeled with antibodies against CD90-APC, EpCAM-
PE-Cy7 (eBioscience), and CD133 (Miltenyi) and then 
subjected to a flow cytometry analysis using FACSCalibur 
(Becton Dickinson). The cell cycle was analyzed using 
a BrdU and propidium iodide (PI) staining assay after 
fixation, as previously described [31].
Clinical HCC specimens
HCC tumor tissue specimens were collected from forty 
HCC patients diagnosed with stage I-IV pathologic tumor-
node-metastasis (TNM) disease [32]. The samples were 
provided by the Tissue Bank at Department of Surgery at 
Queen Mary Hospital. The collection and storage of clinical 
specimens for the Tissue Bank has been approved by the 
Institutional Review Board of the University of Hong Kong/
Hospital Authority of Hong Kong (UW05-3597/I022).
Xenograft tumor model
Cyclin D1-expressing spherical cancer cells (5 × 105 
cells) were subcutaneously injected into 4- or 6-week-old 
severe combined immunodeficiency (SCID) mice. The mice 
were randomized to the respective treatment groups. The 
size of the tumor was monitored based on its luciferin (Gold 
Biotechnology) signal in an IVIS Spectrum in vivo imaging 
system (PerkinElmer). At the end point, volume and weight 
of the tumor were measured. Tumor volume was calculated 
using the formula: tumor volume V = (L × W × W)/2, where 
L is the length of the tumor and W is the width of the tumor. 
Mice were peritoneally injected (I.P.) with 10-40 mg/kg 
SB431542 and 3 mg/kg cisplatin. All mouse experiments 
were approved by the Committee on the Use of Live Animals 
of The University of Hong Kong (CULATR 3240-14).
Statistical analysis
The results for variables are presented as the means 
± SD. Treatment groups were compared with controls using 
a paired or independent Student’s t test. The relationship 
between cyclin D1 and Smad2/3 or Smad4 expression in 
HCC tumors was analyzed using a linear regression. The 
correlation of cyclin D1 with clinicopathological parameters 
was assessed using a crosstab analysis. Differences in patient 
survival were assessed using a Kaplan-Meier analysis. All 
analyses were performed using SPSS 21 (SPSS Inc.). A p 
value < 0.05 was considered statistical significance.
Abbreviations
CSCs, cancer stem cells; HCC, hepatocellular 
carcinoma; iPSCs, induced pluripotent stem cells; 
hESCs, human embryonic stem cells; EMT, epithelial-
mesenchymal transition; 97H, MHCC97H; SB, SB431542; 
cis, cisplatin; oxa, oxaliplatin; dox, doxorubicin
Author contributions
WX, collection and assembly of data, data analysis 
and interpretation; CML, administrative support, provision 
of clinical material and partial financial support; RYCP, 
data analysis and interpretation, study supervision; TTC 
and ACYC, provision of clinical material; CL and SY, 
collection and assembly of data; GSWT, data analysis and 
interpretation, study supervision; XQW, conception and 
design, collection and assembly of data, data analysis and 
interpretation, manuscript writing, financial support, final 
approval of manuscript.
ACKNOWLEDGMENTS AND FUNDING
We thank Dr. R Ng (The University of Hong Kong) 
for providing lentiviral vector. This work was supported 
by Health and Medical Research Fund Research Council 
of Hong Kong to XQ Wang (HMRF 03143396).
Oncotarget38823www.impactjournals.com/oncotarget
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
REFERENCES
1. Kreso A, Dick JE. Evolution of the cancer stem cell model. 
Cell Stem Cell. 2014; 14:275-291.
2. Visvader JE, Lindeman GJ. Cancer stem cells: current 
status and evolving complexities. Cell Stem Cell. 2012; 
10:717-728.
3. Colak S, Medema JP. Cancer stem cells-important players 
in tumor therapy resistance. FEBS J. 2014; 281:4779-4791.
4. Kim JK, Jeon HY, Kim H. The molecular mechanisms 
underlying the therapeutic resistance of cancer stem cells. 
Arch Pharm Res. 2015; 38:389-401.
5. Li Y, Rogoff HA, Keates S, Gao Y, Murikipudi S, Mikule K, 
Leggett D, Li W, Pardee AB, Li CJ. Suppression of cancer 
relapse and metastasis by inhibiting cancer stemness. Proc 
Natl Acad Sci U S A. 2015; 112:1839-1844.
6. Wang Z, Liu Z, Wu X, Chu S, Wang J, Yuan H, Roth M, 
Yuan YC, Bhatia R, Chen W. ATRA-induced cellular 
differentiation and CD38 expression inhibits acquisition of 
BCR-ABL mutations for CML acquired resistance. PLoS 
Genet. 2014; 10:e1004414.
7. Musgrove EA, Caldon CE, Barraclough J, Stone A, 
Sutherland RL. Cyclin D as a therapeutic target in cancer. 
Nat Rev Cancer. 2011; 11:558-572.
8. Takahashi-Yanaga F, Sadaguri T. GSK-3β regulates Cyclin 
D1 expression: a new target for chemotherapy. Cell Signal. 
2008; 20:581-589.
9. Zhao Y, He HR, Wang MY, Ren XD, Zhang L, Dong YL, 
Lu J. Cyclin D1 G870A gene polymorphism and risk of 
leukemia and hepatocellular carcinoma: a meta-analysis. 
Genet Mol Res. 2015; 14:5171-5180.
10. Edel MJ, Menchon C, Menendez S, Consiglio A, Raya A, 
Izpisua Belmonte JC. Rem2 GTPase maintains survival 
of human embryonic stem cells as well as enhancing 
reprogramming by regulating p53 and cyclin D1. Genes 
Dev. 2010; 24:561-573.
11. Ruiz S, Panopoulos AD, Herrerías A, Bissig KD, Lutz M, 
Berggren WT, Verma IM, Izpisua Belmonte JC. A high 
proliferation rate is required for cell reprogramming and 
maintenance of human embryonic stem cell identity. Curr 
Biol. 2011; 21:45-52.
12. Tanabe K, Nakamura M, Narita M, Takahashi K, 
Yamanaka S. Maturation, not initiation, is the major 
roadblock during reprogramming toward pluripotency 
from human fibroblasts. Proc Natl Acad Sci USA. 2013; 
110:12172-12179.
13. Pauklin S, Vallier L. The cell-cycle state of stem cells 
determines cell fate propensity. Cell. 2013; 155:135-147.
14. Dalton S. G1 compartmentalization and cell fate 
coordination. Cell. 2013; 155:13-14.
15. Oshimori N, Fuchs E. The harmonies played by TGF-β in 
stem cell biology. Cell Stem Cell. 2012; 11:751-764.
16. Lonardo E, Hermann PC, Mueller MT, Huber S, Balic 
A, Miranda-Lorenzo I, Zagorac S, Alcala S, Rodriguez-
Arabaolaza I, Ramirez JC, Torres-Ruíz R, Garcia E, Hidalgo 
M, et al. Nodal/Activin signaling drives self-renewal and 
tumorigenicity of pancreatic cancer stem cells and provides 
a target for combined drug therapy. Cell Stem Cell. 2011; 
9:433-446.
17. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, 
Guba M, Bruns CJ, Heeschen C. Distinct populations of 
cancer stem cells determine tumor growth and metastatic 
activity in human pancreatic cancer. Cell Stem Cell. 2007; 
1:313-323.
18. Yamashita T, Honda M, Nakamoto Y, Baba M, Nio K, Hara 
Y, Zeng SS, Hayashi T, Kondo M, Takatori H, Yamashita T, 
Mizukoshi E, Ikeda H, et al. Discrete nature of EpCAM+ 
and CD90+ cancer stem cells in human hepatocellular 
carcinoma. Hepatology. 2013; 57:1484-1497.
19. Ito K, Suda T. Metabolic requirements for the maintenance 
of self-renewing stem cells. Nat Rev Mol Cell Biol. 2014; 
15:243-256.
20. Singh AM, Reynolds D, Cliff T, Ohtsuka S, Mattheyses AL, 
Sun Y, Menendez L, Kulik M, Dalton S. Signaling network 
crosstalk in human pluripotent cells: a Smad2/3-regulated 
switch that controls the balance between self-renewal and 
differentiation. Cell Stem Cell. 2012; 10:312-326.
21. Puisieux A, Brabletz T, Caramel J. Oncogenic roles of 
EMT-inducing transcription factors. Nat Cell Biol. 2014; 
16:488-494.
22. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou 
AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, 
Campbell LL, Polyak K, Brisken C, et al. The epithelial-
mesenchymal transition generates cells with properties of 
stem cells. Cell. 2008; 133:704-715.
23. Menendez JA, Jorge J, Cuff S, Corominas-Faja B, Oliveras-
Ferraros C, Cuyàs E, Martin-Castillo B, López-Bonet E, 
Alarcón T, Vazquez-Martin A. The Warburg effect version 
2.0: metabolic reprogramming of cancer stem cells. Cell 
Cycle. 2013; 12:1166-1179.
24. Agathocleous M, Harris WA. Metabolism in physiological 
cell proliferation and differentiation. Trends Cell Biol. 
2013; 23:484-492.
25. Ward PS, Thompson CB. Signaling in control of cell growth 
and metabolism. Cold Spring Harb Perspect Biol. 2012; 
4:a006783.
26. Wang C, Lisanti MP, Liao DJ. Reviewing once more the 
c-myc and Ras collaboration: converging at the cyclin 
D1-CDK4 complex and challenging basic concepts of 
cancer biology. Cell Cycle. 2011; 10:57-67.
27. Klein EA, Assoian RK. Transcriptional regulation of the 
cyclin D1 gene at a glance. J Cell Sci. 2008; 121:3853-3857.
28. Pestell RG. New roles of cyclin D1. Am J Pathol. 2013; 
183:3-9.
Oncotarget38824www.impactjournals.com/oncotarget
29. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, Wang 
L, Zhou J, Qiu SJ, Li Y, Ji XN, Liu H, Xia JL, et al. A 
decade’s studies on metastasis of hepatocellular carcinoma. 
J Cancer Res Clin Oncol. 2004; 130:187–196.
30. Wang XQ, Lui EL, Cai Q, Ching WY, Liu KS, Poon RT, Fan 
ST. p27Kip1 promotes migration of metastatic hepatocellular 
carcinoma cells. Tumour Biol. 2008; 29:217-223.
31. Wang X, Lui VC, Poon RT, Lu P, Poon RY. DNA damage 
mediated s and g(2) checkpoints in human embryonal 
carcinoma cells. Stem Cells. 2009; 27:568-576.
32. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, 
Haller DG, Morrow M, eds. AJCC cancer staging manual, 
6th edn. TNM classification of malignant tumors. New York: 
Springer, 2002.C22.
